TO COLLABORATION AGREEMENT. This Amendment No. 1 to Collaboration Agreement (the "Amendment"), effective as of May 1, 1998 (the "Amendment Effective Date"), is entered into by and between Symyx Technologies ("Symyx"), a California corporation having a principal place of business at 3100 Xxxxxxx Xxxxxxxxxx, Xxxxx Xxxxx, Xxxxxxxxxx, xxd Bayex XX ("Xayex"), a German corporation having a principal place of business at D-51000 Xxxxxxxxxx, Xxxxxxx, xxd amends that certain Collaboration Agreement entered into by and between Symyx and Bayer effective as of March 1, 1998 (the "Collaboration Agreement").
TO COLLABORATION AGREEMENT. This Amendment No. 1 , (this “Amendment”) dated as of June 28, 2021 (the “Effective Date”), to that certain Collaboration Agreement, dated as of December 10, 2020 (the “Agreement”), by and between, on the one hand, Fusion Pharmaceuticals, Inc., a Canadian federal corporation with its registered offices at 200 Xxxxxxxx Xxxx X, Xxxxxxxx, Xxxxxxx X0X 0X0, Xxxxxx (“FPI”) and, on the other hand, TRIUMF Innovations Inc. (“TI”), a not-for-profit corporation continued under the Canada Not-for-profit Corporations Act, with its registered offices at 4000 Xxxxxxxx Xxxx, Xxxxxxxxx XX X0X 0X0, Xxxxxx and TRIUMF JV, a joint venture of The Governors of The University of Alberta, The University of British Columbia, The Governors of the University of Calgary, Carleton University, University of Guelph, University of Manitoba, McMaster University, Université de Montréal, Queen’s University, University of Rxxxxx, Sxxxx Xxxxxx University, The Governing Council of the University of Toronto, The University of Victoria and York University, and such other universities who have become or may become full members established pursuant to a contract governed by the laws of the Province of British Columbia, having its principal place of business at 4000 Xxxxxxxx Xxxx, Xxxxxxxxx XX X0X 0X0, Xxxxxx (collectively, TRIUMF Innovations Inc. and TRIUMF JV, “TRIUMF”). Each of FPI, TI and TRIUMF JV may be referred to herein as a “Party” or together as the “Parties.” BACKGROUND
TO COLLABORATION AGREEMENT. This Amendment No. 1 to Collaboration Agreement (this "Amendment") is made --------- as of this 12th day of November, 1999 (the "Amendment Effective Date"), by and ------------------------ between Orchid Biocomputer, Inc., a Delaware corporation with a principal place of business at 000 Xxxxxxx Xxxx Xxxx, Xxxxxxxxx, Xxx Xxxxxx 00000 ("ORCHID") and Affymetrix, Inc., a Delaware corporation with a principal place of business at 0000 Xxxxxxx Xxxxxxxxxx, Xxxxx Xxxxx, Xxxxxxxxxx 00000 ("AFFYMETRIX"). Capitalized terms used and not otherwise defined herein shall have the respective meanings ascribed to them in the Collaboration Agreement by and between ORCHID and AFFYMETRIX dated as of November 5, 1999 (the "Agreement"). ---------
TO COLLABORATION AGREEMENT. This Amendment No. 1 to the Collaboration Agreement (this “Amendment”) is entered into and effective as of January 1, 2010 (the “Amendment Effective Date”) by and among MEDIVATION, INC., a Delaware corporation having its principal place of business at 000 Xxxxx Xxxxxx, 0xx Xxxxx, Xxx Xxxxxxxxx, Xxxxxxxxxx 00000, Xxxxxx Xxxxxx, its wholly owned subsidiary Medivation Prostate Therapeutics, Inc., a Delaware corporation having its principal place of business at the same location (such entities, collectively, “Medivation”), ASTELLAS PHARMA INC., a Japanese corporation having a principal office at 3-11, Xxxxxxxxxx-Xxxxxx 0-xxxxx, Xxxx-xx, Xxxxx 000-0000, Xxxxx (“API”) and its indirect wholly owned subsidiary Astellas US LLC, a Delaware limited liability company having its principal place of business at Xxxxx Xxxxxxx Xxxxx, Xxxxxxxxx, Xxxxxxxx 00000, Xxxxxx Xxxxxx (“AUS”; collectively with API, “Astellas”). Medivation and Astellas are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
TO COLLABORATION AGREEMENT. Microsphere Patents ------------------------------- ----------------------------- ---------------------------- Patent App. No. Country Filing Date ------------------------------- ----------------------------- ---------------------------- [***]* [***]* [***]* ------------------------------- ----------------------------- ---------------------------- [***]* --------------------- ------------------ -------------------- ------------- -------------- Patent App. No. Patent No. Country Filing Date Issue Date --------------------- ------------------ -------------------- ------------- -------------- [***]* [***]* [***]* [***]* [***]* --------------------- ------------------ -------------------- ------------- -------------- [***]* --------------------- ------------------ -------------------- ------------- -------------- Patent App. No. Patent No. Country Filing Date Issue Date --------------------- ------------------ -------------------- ------------- -------------- [***]* [***]* [***]* [***]* [***]* --------------------- ------------------ -------------------- ------------- -------------- [***]* --------------------- ------------------ -------------------- ------------- -------------- Patent App. No. Patent No. Country Filing Date Issue Date --------------------- ------------------ -------------------- ------------- -------------- [***]* [***]* [***]* [***]* [***]* --------------------- ------------------ -------------------- ------------- -------------- [***]* ------------------------------- ----------------------------- ---------------------------- Patent App. No. Country Filing Date ------------------------------- ----------------------------- ---------------------------- [***]* [***]* [***]* ------------------------------- ----------------------------- ---------------------------- [***]* ---------- *[***] indicates confidential treatment for omitted text has been requested. EXHIBIT B TO COLLABORATION AGREEMENT Research Program [***]* ---------- *[***] indicates confidential treatment for omitted text has been requested. EXHIBIT C TO COLLABORATION AGREEMENT List of Third Party Agreements
TO COLLABORATION AGREEMENT. This amendment to the Collaboration Agreement (this “Amendment”) is made and entered into as of the 24th day of January, 2012 (the “Execution Date”), by and between Amgen Inc., a Delaware corporation with a place of business at 0 Xxxxx Xxxxxx Xxxxx, Xxxxxxxx Xxxx, XX 00000 (“Amgen”), and Glaxo Group Limited, registered in England as company number 305979, doing business as “GlaxoSmithKline” and having its principal office at Glaxo Xxxxxxxx Xxxxx, Xxxxxxx Xxxxxx, Xxxxxxxxx, Xxxxxxxxx, XX0 0XX, Xxxxxx Xxxxxxx (“GSK”).
TO COLLABORATION AGREEMENT. This Amendment No. 1 to Collaboration Agreement (the “Amendment”) is made as of April 14, 2009 (the “Amendment Effective Date”) to amend that certain Collaboration Agreement dated as of November 3, 2006 (the “Agreement”) by and between Cephalon, Inc., a Delaware corporation with its principal place of business located at 00 Xxxxxx Xxxx, Xxxxxx, Pennsylvania 19355 (“Cephalon”), and Ambit Biosciences Corporation, a Delaware corporation, having a principal place of business at 0000 Xxxxxxxx Xxxxxx Xxxx, Xxx Xxxxx, Xxxxxxxxxx 00000 (“Ambit,” together with Cephalon, the “Parties”).
TO COLLABORATION AGREEMENT. This Amendment No. 1 to Collaboration Agreement (the “Amendment”) effective as of the 7th day of November, 2022 (the “Amendment Effective Date”) entered into by and between Seagen Inc. (f/k/a Seattle Genetics, Inc.) having its principal place of business at 00000 00xx Xxxxx X.X., Xxxxxxx, XX 00000 XXX (hereinafter referred to as “SGI”) and Takeda Manufacturing U.S.A., Inc. (successor by assignment from Millennium Pharmaceuticals, Inc.) having its principal place of business at 00 Xxxxxx Xxxxxx, Xxxxxxxxx, XX 00000 XXX (hereinafter referred to as "Takeda"). In this Amendment SGI and Takeda may be individually referred to as “Party”, or collectively referred to as “Parties”. RECITALS WHEREAS, SGI and Takeda are parties to that certain Collaboration Agreement dated December 14, 2009 (the “Agreement”); and
TO COLLABORATION AGREEMENT. Dear Xxxx, This letter amendment (“Amendment No. 3”), effective as of June 9, 2008, is in reference to the Collaboration Agreement dated April 14, 2002 (the “Collaboration Agreement”), as amended by Amendment No. 1 to the Collaboration Agreement effective on June 24, 2003 (“Amendment No. 1”) and Amendment No. 2 to the Collaboration Agreement effective on December 22, 2004 (“Amendment No. 2”) (the Collaboration Agreement, Amendment No. 1 and Amendment No.2 are collectively referred to herein as, the “Agreement”), by and between Adolor Corporation (“Adolor”) and Glaxo Group Limited (“GGL”). All capitalized terms used in this Amendment No. 3 that are not otherwise defined herein shall have the meanings given to them in the Agreement. Notwithstanding anything to the contrary in the Agreement, the terms pursuant to which GSK shall deploy and pay incentive compensation to the GSK Sales Representatives during the period beginning on the date of the First Commercial Sale of the POI Product in the United States until December 31, 2008 (the “Launch Period”) shall be as follows: Subject to an annual [**] percent [**] vacancy rate, GSK shall deploy not less than [**] GSK Sales Representatives to Detail the POI Product to the Target Audience in the United States during the Launch Period. The Parties acknowledge and agree that a GSK Sales Representative shall mean and include those individuals referred to internally by GSK in the United States as “Account Managers” who are hospital based. This deployment of GSK Sales Representatives as set forth in this Amendment No. 3 shall be considered as the Sales Representative FTE Requirements for GSK during the Launch Period. Further, during the Launch Period, GSK will not categorize the GSK Sales Representatives as Hospital Account Managers, Oncology Account Managers or Surgical Account Managers.
TO COLLABORATION AGREEMENT. This Amendment No. 1 (the “First Amendment”) is effective as of January 1, 2013 (the “First Amendment Effective Date”) by and between Astellas Pharma Inc. (“Astellas”) and FibroGen, Inc. (“FG”). This First Amendment amends the Collaboration Agreement entered into by and between Astellas and FG on June 1, 2005 (the “Agreement”). Astellas and FG shall be referred to individually herein as a “Party” and collectively as the “Parties”.
